Related Experiment Video
Updated: May 13, 2026

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
Published on: July 16, 2021
Computational modeling of ATM signaling: a predictive framework for drug repurposing in ataxia-telangiectasia
Aurora Eliana Merulla1, Valentina Di Salvatore2, Giorgia Serena Gullotta3
1Department of Physics and Astronomy, University of Catania, Catania, Italy.
Abstract:
Ataxia-Telangiectasia (A-T) is a rare genetic disorder caused by ATM mutations, leading to impaired DNA repair, oxidative stress, and neurodegeneration. We developed a computational model of ATM-mediated signaling using ordinary differential equations in COPASI, capturing key processes including DNA damage sensing, cell cycle regulation, autophagy, and oxidative stress response. The model simulates physiological, ATM-deficient, and drug-treated conditions to explore repurposing strategies. We evaluated the effects of spermidine, omaveloxolone, and HDAC4 inhibition, revealing mechanisms by which these compounds modulate dysfunctional signaling. Sensitivity and stability analyses confirmed the model's robustness, while enrichment analysis validated involvement of key pathways. Our results highlight the synergistic potential of combining autophagy activation and epigenetic modulation to partially restore homeostasis in ATM-deficient cells. This work introduces a generalizable modeling framework for simulating disease-specific signaling dysfunction and identifying therapeutic interventions, illustrating the value of computational systems biology in rare disease drug repurposing.
More Related Videos
08:41Author Spotlight: Deciphering the Role of ATM in Ataxia-Telangiectasia and the Associated Cerebellar Degeneration
Published on: December 27, 2024
08:04Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
Published on: June 6, 2025
Related Concept Videos
Pharmacodynamic Models: Overview
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions